Navigation Links
Par Pharmaceutical Companies Reports Third Quarter 2011 Results
Date:11/2/2011

settlements and contingencies

-2,250Non-cash interest expense

-533Abrika earn-out payment

-(3,567)Sum of adjustments, pre-tax

$2,852$1,216Estimated tax on adjustments

551(462)Domestic manufacturing tax benefit

-(2,009)Adjusted Income from Continuing Operations (non-GAAP measure)

$25,458$29,406Amortization Expense

2,5483,079Estimated tax impact

(943)(1,170)Amortization Expense, net of tax

1,6051,909Adjusted Cash basis from Continuing Operations (non-GAAP measure)27,06331,315"Cash EPS" from Continuing Operations (non-GAAP measure)$0.74$0.88Diluted weighted average shares outstanding

36,77435,684Nine Months EndedSeptember 30,September 30,20112010(Loss) Income from Continuing Operations($77,609)$75,122Litigation settlements and contingencies, pre-tax

190,560(1,880)Restructuring costs

27,660-Transaction costs for Edict and Anchen

2,852-Upfront and development milestone payments

-19,000Sale of product rights

-(5,000)Non-cash interest expense

-1,571Abrika earn-out payment

-(3,567)Sum of adjustments, pre-tax

$221,072$10,124Estimated tax on adjustments

(58,397)(3,847)Charge related to valuation of deferred income tax assets

2,391-Resolution of tax contingencies

-(3,657)Domestic manufacturing tax benefit

-(2,009)Adjusted Income from Continuing Operations (non-GAAP measure)

$87,457$75,733Amortization Expense

8,66611,233Estimated tax impact

(3,238)(4,269)Amortization Expense, net of tax

5,4286,964Adjusted Cash basis from Continuing Operations (non-GAAP measure)92,88582,697"Cash EPS" from Continuing Operations (non-GAAP measure)$2.54$2.34Diluted weighted average shares outstanding

36,52535,410
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... LONDON , December 15, 2014 /PRNewswire/ ... Am 19. und 20. Februar ... das Aegate SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ... zu besuchen. Diese Tagung ... Gemeinschaft die Möglichkeit geben, die neue profitablen ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ) ... Cava (IVC) Filters - Global Trends, Estimates and Forecasts, ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior Vena ... million by 2016. The North America ... value while Europe claims approximately ...
(Date:12/15/2014)... and HERZLIYA PITUACH, Israel , Dec. ... IMNP ) announced today that its Board of ... succeeding Dr. Daniel Teper who continues as Chief ... of Immune,s Board of Directors since 2013. Immune,s ... delighted to represent the interest of shareholders and to continue ...
Breaking Medicine Technology:Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
...   Sanofi (EURONEXT: SAN and NYSE: ... Scientific American Diabetes Association Sessions,2011, the results of three studies ... and/or,Apidra ® with the insulin delivery device,SoloSTAR ® ... of hypoglycemia vs those,using a premixed insulin product. ...
... June 24, 2011 Advanced BioHealing, Inc. ... technology in the field of regenerative medicine, today announced ... Lewin Group (Falls Church, VA) that showed the addition ... chronic diabetic foot ulcers (DFUs) resulted in a significant ...
Cached Medicine Technology:Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 2Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 3Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 4Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 5Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 6Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 7Health Economics Model Shows That Dermagraft® Combined With Conventional Care is a Cost-Effective Treatment for Diabetic Foot Ulcers in Medicare and Commercially Insured Populations 2Health Economics Model Shows That Dermagraft® Combined With Conventional Care is a Cost-Effective Treatment for Diabetic Foot Ulcers in Medicare and Commercially Insured Populations 3Health Economics Model Shows That Dermagraft® Combined With Conventional Care is a Cost-Effective Treatment for Diabetic Foot Ulcers in Medicare and Commercially Insured Populations 4Health Economics Model Shows That Dermagraft® Combined With Conventional Care is a Cost-Effective Treatment for Diabetic Foot Ulcers in Medicare and Commercially Insured Populations 5
(Date:12/17/2014)... Poor students get more fruits and vegetables at school than ... the opposite is true for students from wealthier families. ... may give a healthy boost to poor students, diets, according ... income level, students all ate a similar amount of fruits ... was published recently in the journal Preventive Medicine . ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, 2014 (HealthDay ... health, but a growing body of evidence shows the ancient ... In fact, the benefits were similar to those of ... Chu, a doctoral candidate at Harvard University,s Health Policy Program ... that people randomly assigned to take yoga classes saw improvements ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Cancer researchers ... possible underlying genetic causes of deadly malignant pleural mesothelioma. ... research on their website. Click here to read ... University of Hawaii Cancer Center, and New York’s Langone ... malignant pleural mesothelioma patients in an effort to ...
(Date:12/15/2014)... Palm Beach, FL (PRWEB) December 15, 2014 ... Care , knows that holidays can be a daze of ... From slips and falls while decking halls, to burns when ... plenty of holiday hazards that can happen at any time. ... for pain, MD Now has made a list of helpful ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Health ... solutions, announced today that it has received Patient ... Assurance (NCQA) for its Disease Management (DM) Programs ... disease (COPD), coronary heart disease and diabetes. This ... NCQA for Health Dialog’s Disease Management (DM) Programs, ...
Breaking Medicine News(10 mins):Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2
... Real Parental Reassurance, NEW YORK, May 22 ... of biosensor and microprocessor technologies for,use in portable ... for its latest homecare wellness product using SPO,s ... traditional home baby,monitor market., Each year, there ...
... at ... Alma Mater, ... of two fellowships totaling $500,000,in honor of former Chief Executive Officer ... Dr. Garnier, who,received his Masters of Business Administration from the school ...
... SUPPORTS AMERICA,S NEXT GENERATION OF SCIENTISTS, WASHINGTON, ... (the Alliance) announced today the establishment of the,Alliance/Merck ... access to higher education and degrees in science,technology, ... possible,through a $4 million grant from The Merck ...
... Reach of Novel Technology, N. BILLERICA, Mass., ... of cellular bioenergetics, announced today,that Primetech Corporation will ... consumables in Japan., "Japan,s contribution to research ... have seen with the recent acquisition of Millennium ...
... 22 /Xinhua-PRNewswire-FirstCall/ --,China Biologic Products, Inc. (OTC Bulletin ... leading plasma-based pharmaceutical companies in the,People,s Republic of ... from the Bureau of Health in Guangxi Province ... to a more favorable,location with a wider coverage ...
... projected to climb at double-digit rates, ... according to Millennium Research Group, WALTHAM, Mass., ... for Craniomaxillofacial (CMF) Devices 2008 report,the plate and screw fixation ... nearly $300 million in 2012, driven in part by the ...
Cached Medicine News:Health News:SPO Medical Announces Entry into the Global Baby Monitor Consumer Market 2Health News:SPO Medical Announces Entry into the Global Baby Monitor Consumer Market 3Health News:GlaxoSmithKline Announces $500,000 in Fellowships at Stanford Graduate School of Business 2Health News:GlaxoSmithKline Announces $500,000 in Fellowships at Stanford Graduate School of Business 3Health News:Alliance/Merck Ciencia (Science) Hispanic Scholars Program Announced 2Health News:Alliance/Merck Ciencia (Science) Hispanic Scholars Program Announced 3Health News:Alliance/Merck Ciencia (Science) Hispanic Scholars Program Announced 4Health News:Seahorse Bioscience Enters into Agreement with Primetech Corporation to Bring XF Technology to Japanese Market 2Health News:China Biologic Products Announces Approval for the Relocation of Fang Cheng Plasma Collection Station and for the Procurement of Excess Clinical Plasma 2Health News:China Biologic Products Announces Approval for the Relocation of Fang Cheng Plasma Collection Station and for the Procurement of Excess Clinical Plasma 3Health News:Craniomaxillofacial Plate & Screw Market To Grow to Almost $300 Million by 2012 2
... is a electronic medical records software for ... The Medical Office Records does more than ... designed to follow the flow of your ... previous encounters to establishing new examination records ...
... ChartMaker is a modular, Electronic Medical Record ... Windows to create a patient chart. ChartMaker ... E & M compliant patient notes, medical reports, ... template driven, ChartMaker is designed to be installed ...
... The eCHARMS suite comprises the ... 2000 product line. Currently, there ... signature & enterprise-wide disclosure reporting. ... new HIM management tool. These ...
Clinician's Desktop provides users the tools needed to coordinate information. Utilizing client/server technology Clinicians Desktop provides users with electronic medical records....
Medicine Products: